Hangzhou Innoforce Raises $96 Million for CRO/CDMO Biopharma Services
March 22, 2021 at 07:27 AM EDT
Hangzhou Innoforce Pharma completed a $96 million Series A financing to support its CRO/CDMO and biomanufacturing services. Innoforce earmarked the proceeds to build a large campus for its operations in Hangzhou Bay Biotech Valley . The first phase of construction will cover 590,550 square feet and will meet international GMP standards for biologic manufacturing and bioprocess development laboratories. In addition to standard CRO services, Innoforce plans to offer equity investment to select partners. More details.... Share this with colleagues: // //
